News

At 8 weeks, treatment with ninerafaxstat demonstrated clinically and statistically significant improvements in dobutamine stress-induced ischemic left ventricular (LV) wall motion abnormalities.

CHAPEL HILL, N.C.-- Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that...

The PREVENT risk calculator uniquely quantifies risks for CVD for each biological sex. As more research has been conducted specifically in women, this is an important way to understand their unique differences in CVD presentation and risk...

This expert consensus offers a more differentiated definition of heart attacks and improves the understanding of acute atherothrombotic myocardial infarction.

In the patient-level pooled analysis, titled “Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes,” use of IVL for lesion preparation of severely calcified lesions had similar safety...

The RADIANCE global program studied the Paradise system in three independently powered, sham-controlled, randomized clinical trials in over 500 patients with uncontrolled hypertension.

DALLAS – Measuring blood pressure while patients are standing rather than sitting may improve the accuracy of readings, UT Southwestern Medical Center researchers report. Their findings, published in Scientific Reports, could lead...

At 12-weeks, treatment with ninerafaxstat showed a statistically significant improvement in a robust functional cardiopulmonary exercise test (CPET) measure of established prognostic significance in patients with nHCM and heart failure with...

  ZACHARY, LA– Dr. Charles Thompson, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in Louisiana to use the Auryon Laser Atherectomy System by AngioDynamics, Inc. in a hospital setting to...

The 107-patient, prospective, non-randomized, multicenter, single-arm study evaluates the Bare Temporary Spur Stent System in combination with a paclitaxel-coated balloon in patients with below-the-knee arterial disease.